Stock Ratings / Health Care / PDEX / financials

KTWO (53) UTMD (63) PROF (47) STIM (31) ⌘ Pro Terminal →

Pro-Dex Inc. (PDEX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$61.60 -2.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $61.20

Pro-Dex Inc. (PDEX) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY) →

ROARABLE D • SELL / AVOID Cap $199.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $61.21 (-0.64%)🧬 Disciplined Float (+0.52% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY • 49.7% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-3.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PDEX)Realized 20D OHLCV Swing Band: ±9.6%

Deterministic 5-Pillar Attribution (51/100 Composite)

🔍 WHY PDEX SCORES 51/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (31% of score)

Altman Z-Score 9.08 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+11/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 29.3% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$62.49-6.8% Next Q

Q2 (-2Q)

Grade C$58.26+6.8% Next Q

Q3 (-1Q)

Grade C-$62.22-1% Next Q

Current

Grade D$61.60-1.3% Hist 90D α

Trajectory: C (59) → D (51)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PDEX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PDEX currently carries a cautious 51/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Clean SEC annual filing review with no major hidden accounting time-bombs.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($64.77) and Max Pain ($64.68) forces dealer call-delta covering toward $80.85.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.52% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PDEX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PDEX Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 51%NO 49%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How PDEX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $46.1M

FY24

Rev $53.8M

FY25

Rev $66.6M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$66.6M	29.3%	16.1%	$9.0M	-$2.9M	23.2%
FY 2024	$53.8M	27%	13.3%	$2.1M	$6.2M	17.8%
FY 2023	$46.1M	29.3%	12.5%	$7.1M	$5.5M	23.2%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PDEX)

✓Walkthrough of PDEX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PDEX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +22.86%▲ ASCENDING CHANNEL

2026-10-30O $63.15H $65.65L $57.62C $61.60VOL 38.5K

RES: $81.73SUP: $56.44SMA50: $64.77SMA200: $56.56

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PDEX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PDEX Butterfly Map → + Track PDEX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

15.9%/yr Implied 5Y Growth

vs. +23.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PDEX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PDEX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PDEX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PDEX)

Health Care Rank #337 of 1016 ⚔️ KTWO vs PDEX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PDEX vs. KTWO, UTMD, PROF, STIM)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Pro-Dex Inc. (PDEX) ranks #337 by composite RQD confidence (51/100, grade D) and #579 by equity capitalization ($199.2M). Within this direct 5-issuer industry benchmark cohort, PDEX leads on earnings valuation at 22.2x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. UTMD currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with PDEX at 51/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PDEX ACTIVE Pro-Dex Inc.	D	51/100	22.2x	29.3%	23.2%	-2.52%	$199.2M	Benchmark Subject
KTWO K2 Capital Acquisition Corporation Class A Ordinary Share	D+	53/100	—	—	—	+0.30%	$202.8M	/ktwo-vs-pdex →
UTMD Utah Medical Products Inc.	C	63/100	—	57.1%	26.9%	-2.96%	$212.7M	/utmd-vs-pdex →
PROF Profound Medical Corp.	D	47/100	—	70.8%	-35.0%	+1.38%	$214.1M	/prof-vs-pdex →
STIM Neuronetics Inc.	E	31/100	—	48.5%	-35.0%	+5.31%	$181.3M	/stim-vs-pdex →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0000788920

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Pro-Dex Inc. (PDEX) reported GAAP revenue of $66.6M (+23.7% vs. FY2024 revenue of $53.8M , and +44.5% cumulative change since FY2023) , GAAP net income of $9.0M, operating cash flow of -$1.7M, and free cash flow of -$2.9M (-147.0% YoY). On the balance sheet, PDEX closed FY2025 with $62.3M in total assets against $0 in total debt (Altman Z-Score: 9.08, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$66.6M	$9.0M	-$1.7M	-$2.9M	$62.3M	—
FY2024 (FY)	2024-06-30	$53.8M	$2.1M	$6.2M	$6.2M	$60.4M	—
FY2023 (FY)	2023-06-30	$46.1M	$7.1M	$5.5M	$5.5M	—	—

3. PDEX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PDEX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Pro-Dex Inc. (NASDAQ: PDEX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $61.60 (-2.52% 1D, market cap $199.2M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, PDEX ranks #337 in composite RQD confidence.

How does PDEX compare to KTWO and UTMD in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), PDEX carries a Roarable D (51/100 RQD), trailing P/E of 22.2x, gross margin of 29.3%, and ROIC of 23.2%. By comparison, KTWO (K2 Capital Acquisition Corporation Class A Ordinary Share) holds a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $202.8M) and UTMD (Utah Medical Products Inc.) posts a C grade (63/100 RQD, P/E N/A, ROIC 26.9%, cap $212.7M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PDEX?

Per PDEX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000788920), Pro-Dex Inc. generated $66.6M in revenue (+23.7% YoY), $9.0M in net income, and -$2.9M in free cash flow against $62.3M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PDEX trading relative to its 50-day, 200-day, and 52-week technical levels?

PDEX last traded at $61.60 (-2.52% on volume of 43,107 shares), positioning the stock -4.89% below its 50-day simple moving average ($64.77) and +8.91% above its 200-day simple moving average ($56.56). Across its 52-week range of $28.81 to $77.00, PDEX sits at the 68.0% percentile with a 14-day RSI of 38.5 (NEUTRAL RANGE) and an implied next-earnings move of ±9.6% ($55.69 to $67.51).

PDEX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Pro-Dex Inc. (PDEX)?

In FY 2025 (10-K), PDEX converted $66.6M of revenue into a 29.3% gross margin, 16.1% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: PDEX RQD Cockpit PDEX 12M Forecast PDEX Earnings & Move PDEX Dividends & DRIP PDEX Insiders & 13F PDEX Whale Options PDEX Profit Sankey PDEX News & Why